Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvelo Biosciences Inc

Evelo Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
133
Market Cap
0.00M

Momentum Score

…

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered biologic therapies intended to modulate the gut-immune axis for inflammatory and immuno-oncology indications. Long-term growth may be driven by positive clinical trial readouts, regulatory approvals, scalable manufacturing and commercial partnerships, and increasing scientific interest in microbiome-linked approaches, which could support future revenue if programs reach the market.
Material risks include high clinical and regulatory uncertainty, ongoing negative cash flow and fundraising needs, the potential for program failures, and limited liquidity and disclosure typical of small PINK-listed biotech stocks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-10.24
ROE
-6232.76%
Net Debt
3.20M
ROCE
-142.83%
Diluted EPS TTM
-3.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -81.44M -113.60M -121.75M -93.26M -85.47M
Net income -82.35M -114.53M -122.18M -93.67M -85.66M
Selling general administrative 20.85M 29.91M 31.75M 22.27M 23.23M
Reconciled depreciation 1.56M 2.06M 2.22M 2.03M 1.76M
Ebit - -108.47M -115.40M -93.91M -88.12M
Ebitda - -108.41M -114.91M -91.89M -86.36M
Depreciation and amortization - 0.06M 0.49M 2.03M 1.76M
Non operating income net other - - -6.35M -1.37M 1.07M
Operating income -74.33M -108.47M -115.40M -91.89M -86.36M
Other operating expenses - 108.47M 115.40M 91.89M 86.36M
Interest expense 5.48M 4.67M 3.61M 2.11M 1.05M
Tax provision 0.91M 0.93M 0.43M 0.41M 0.19M
Interest income - - - - 1.05M
Net interest income -5.48M -4.67M -3.61M -2.11M 1.05M
Income tax expense - 0.93M 0.43M 0.41M 0.19M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 74.33M 108.47M 115.40M 91.89M 86.36M
Total other income expense net -1.63M -5.13M -6.35M -1.37M 0.89M
Net income from continuing ops -82.35M -114.53M -122.18M -93.67M -85.47M
Net income applicable to common shares - -114.53M -122.18M -93.67M -85.47M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 64.44M 87.87M 90.64M 90.92M 159.87M
Other current assets 3.63M 2.58M 2.12M 3.18M 3.70M
Total liab 69.43M 79.20M 60.15M 30.72M 22.92M
Total stockholder equity -4.99M 8.67M 30.48M 60.20M 136.95M
Deferred long term liab - 7.50M - 1.15M 1.07M
Other current liab 0.87M 0.74M 0.46M 9.12M 7.72M
Common stock 0.11M 0.05M 0.05M 0.03M 0.03M
Capital stock 0.11M 0.05M 0.05M 0.03M 0.03M
Retained earnings -529.22M -414.69M -292.52M -198.85M -113.38M
Other liab 8.16M 7.50M 0.28M 1.35M 1.38M
Other assets 1.16M 1.31M 12.18M 1.57M 1.32M
Cash 47.94M 68.44M 68.86M 77.83M 147.92M
Total current liabilities 12.39M 17.36M 19.83M 9.74M 9.23M
Current deferred revenue 7.50M 13.07M -2.14M - -
Net debt 3.20M -12.15M -28.82M -58.20M -135.61M
Short term debt 2.26M 1.95M 1.67M - -
Short long term debt total 51.14M 56.29M 40.04M 19.63M 12.30M
Other stockholder equity 524.12M 423.31M 322.96M 259.02M 90.45M
Property plant equipment 11.71M 6.62M 7.48M 8.34M 6.92M
Total current assets 51.57M 71.03M 68.86M 77.83M 147.92M
Net tangible assets -4.99M 8.67M 30.48M 60.20M 136.95M
Short term investments - - - 0.00M 54.82M
Long term debt 43.61M 46.56M 30.05M 19.63M 12.30M
Accounts payable 1.76M 1.60M 19.83M 9.74M 9.23M
Accumulated other comprehensive income - - - -90.92M -0.02M
Common stock total equity - 0.05M 0.05M 0.03M 0.03M
Retained earnings total equity - -414.69M -292.52M -198.85M -113.38M
Non currrent assets other 1.16M 1.31M 3.55M 4.75M 5.02M
Non current assets total 12.87M 16.84M 21.78M 13.09M 11.95M
Capital lease obligations 7.52M 9.74M 11.66M - -
Long term debt total - 46.56M 30.05M 19.63M 12.30M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.27M -0.62M -1.48M -1.31M 55.00M
Change to liabilities - 0.17M -2.88M 8.48M 3.10M
Total cashflows from investing activities - -0.62M -1.48M -1.31M 51.97M
Net borrowings - -3.12M 14.78M 10.00M 4.48M
Total cash from financing activities 20.76M 81.66M 97.54M 65.47M 4.99M
Change to operating activities - -9.84M -5.59M 6.93M 4.06M
Net income -82.35M -114.53M -122.18M -93.67M -85.47M
Change in cash -52.15M -20.66M -0.67M -8.91M -15.02M
Begin period cash flow 70.21M 69.75M 70.42M 79.33M 94.35M
End period cash flow 17.54M 49.10M 69.75M 70.42M 79.33M
Total cash from operating activities -73.70M -101.23M -96.72M -73.06M -71.98M
Issuance of capital stock 29.17M 84.54M 81.75M 54.99M 0.00M
Depreciation 1.56M 2.06M 2.22M 2.03M 1.76M
Other cashflows from investing activities - - 0.04M 0.01M 0.00M
Sale purchase of stock - - 1.01M 55.47M 0.51M
Other cashflows from financing activities - 44.72M 15.79M 10.47M 19.99M
Change to netincome - 20.90M 19.32M 8.84M 8.42M
Capital expenditures 0.29M 0.62M 1.52M 1.32M 3.03M
Cash flows other operating - - 6.80M 1.26M 0.37M
Cash and cash equivalents changes - - -0.67M -8.91M -15.02M
Change in working capital -11.79M -9.67M 2.07M 7.76M 3.47M
Stock based compensation 11.17M 15.16M 15.85M 8.47M 8.16M
Other non cash items 5.73M 5.74M 2.10M 2.35M 0.26M
Free cash flow -73.99M -101.86M -98.24M -74.38M -75.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EVLO
Evelo Biosciences Inc		 -
-%		 0.00 - - - 3.51 -0.39
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Evelo Biosciences Inc

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

600/700, One Kendall Square, Cambridge, MA, United States, 02139

617 577 0300

https://www.evelobio.com

66

Name Title Year Born
Dr. Balkrishan Gill Ph.D. Pres, CEO & Director 1965
Dr. Jonathan B. Zung Ph.D. Chief Devel. Officer 1965
Ms. Marella Thorell CFO & Treasurer 1967
Mr. Stephen J. Carriere VP & Chief Accounting Officer 1955
Dr. Chun Zhang Ph.D. Chief Technical Operations & Quality Officer NA
Dr. Mark Bodmer Ph.D. Chief Scientific Officer and Pres of R&D 1958
Ms. Kendra Sweeney Head of Investor Relations & Capital Markets NA
Ms. Jessica Cotrone VP & Head of Communications NA
Ms. Leslie Wardwell-Scott Ph.D. VP and Head of Corp. Devel. & Strategic Integration NA
Ms. Julie Carretero Chief People Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…